KRAS and cancer: Combined genetic or pharmacological inhibition of ERK5 and CDK5 triggered ROS-induced DNA damage and apoptosis in cancer cells and mouse models of KRAS-driven lung adenocarcinoma, recapitulating FAK pharmacological inhibition.